Novo Nordisk A Slash S
Novo Nordisk A/S, headquartered in Denmark (DK), is a global leader in the pharmaceutical industry, specialising in diabetes care, obesity management, and hormone replacement therapies. Founded in 1923, the company has achieved significant milestones, including the development of innovative insulin products and GLP-1 receptor agonists that have transformed diabetes treatment. With a strong presence in Europe, North America, and Asia, Novo Nordisk is renowned for its commitment to sustainability and patient-centric solutions. Its core products, such as insulin pens and diabetes management devices, are distinguished by their advanced technology and user-friendly design. As a pioneer in diabetes care, Novo Nordisk holds a prominent market position, consistently recognised for its contributions to improving patient outcomes and advancing healthcare globally.
DitchCarbon Score
How does Novo Nordisk A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk A Slash S's score of 73 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novo Nordisk A Slash S's reported carbon emissions
In 2023, Novo Nordisk A/S reported total carbon emissions of approximately 3,831,000,000 kg CO2e. This figure includes 78,000,000 kg CO2e from Scope 1 emissions, 15,000,000 kg CO2e from Scope 2 emissions, and a significant 1,743,000,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for net-zero emissions across its entire value chain by 2045. To achieve these goals, Novo Nordisk has established several key reduction targets. By 2030, the company aims to reduce its absolute Scope 1 and 2 emissions by 100% from a 2024 base year. Additionally, it plans to cut its Scope 3 emissions by 33% by 2033, also compared to a 2024 baseline. This includes emissions from purchased goods and services, capital goods, and transportation. Historically, in 2019, Novo Nordisk's total emissions were about 306,000,000 kg CO2e, with Scope 1 and 2 emissions totalling 161,000,000 kg CO2e. The company has made significant strides in reducing its carbon footprint, reflecting a commitment to sustainability and environmental responsibility within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 145,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk A Slash S is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
